Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action

Journal of Physiology and Pharmacology

Volumn 50, Issue 1, 1999, Pages 99-109

  Chabielska, E ^a   Pawlak, R ^a   Wollny, T ^a   Rolkowski R ^b   Buczko, W ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Centre of Oncology   (Poland)

Author keywords

Losartan; Nitric oxide; Renal hypertensive rats; Venous thrombosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; LOSARTAN; LOSARTAN POTASSIUM; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ANIMALS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HYPERTENSION, RENAL; KIDNEY; LOSARTAN; MALE; NITRIC OXIDE; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN; STRUCTURE-ACTIVITY RELATIONSHIP; VENOUS THROMBOSIS;

EID: 0032905788     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Feener EP, Northrp JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 5: 1353-1362.
2. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
3. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
4. Ding YA, Mac Intyre DE, Kenyon CH, Semple P. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost 1985; 54: 717-720.
5. Chobanian AV, Haudenschild ChC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanable Heritable hiperlipidemic rabbit. Hypertension 1992; 15: 327-331.
6. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
7. Pitt B, Segal R, Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
8. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26: 236-243.
9. Jaiswal N, Diz DI, Tallant A, Khosla MC, Ferrario CM. The nonpeptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens 1991; 4: 228-233.
10. 2 receptors stimulation increases aortic cyclic GMP levels in SHRSP by kinin-dependent mechanism. Hypertension 1998; 31: 349-355.
11. Chabielska E, Pawlak R, Golatowski J, Rółkowski R, Pawlak D, Buczko W. Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats. Thromb Res 1998; 90: 271-278.
12. Shiono K, Sokabe H. Renin-angiotensin system in spontaneously hypertensive rats. Am J Physiol 1976; 231: 1295-1299.
13. Ikeda K, Nara Y, Yamori Y. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats. Lab Animals 1991; 25: 26-29.
14. Reyers I, de Gaetano G, Donati MB. Venostasis-induced thrombosis in rat is not influenced by circulating platelet or leukocyte number. Agents Actions 1989; 28: 137-140.
15. Born BVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.
16. Radomski MW, Palmer MJR, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-1489.
17. Dejana E, Villa S, de Gaetano G. Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemost 1982; 48: 108-111.
18. Bernat A, Vallee E, Maffrand JP, Gordon JL. The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat. Thromb Res 1988; 52: 65-70.
19. Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987; 17: 329-335.
20. 2 - receptor in endothelial cells and isolaled ischemic rat hearts. Pharm Pharmacol Lett 1993; 3: 24-27.
21. Scheuer DA, Perrone MH. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993; 264: R917-R923.
22. Campbell DJ, Menard J, Azizi M, Gonzales MF. Synergistic interaction between angiotensin converting enzyme inhibition and angiotensin II antagonism in spontaneously hypertensive rats. J Hypertens 1997; 15 (Suppl 4): S 63.
23. Brosnihan KB, Li P, Ferrario C.M. Angiotensin - (1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27: 523-528.
24. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, patophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
25. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-2380.
26. Simon DI, Stamler JS, Loh E, Loscalzo J, Francis SA, Creager MA. Effect of nitric oxide syntase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26: 339-342.
27. Burnier M, Centeno G, Grouzmann E, Walker P, Waeber B, Brunner R. In vitro effects of DuP 753, a nonpeptide angiotensin II receptor antagonist, on human platelets and rat vascular smooth muscle cells. Am J Hypertens 1991; 4: 438-443.
28. 2 (TP) receptors. Prostaglandins 1992; 44: 89-99.
29. 2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998; 32: 198-205.
30. Chabielska E, Pawlak R, Buczko W. Losartan does not influence the blood platelet aggregation in normotensive rats. Acta Physiol Hung 1996; 84: 271-272.
31. Hornstra G, Kalafusz R, Wierts JW, Kester ADM. Does platelet function in vitro reflect thrombosis tendency in vivo? Thromb Haemost 1991; 65: 1085.
32. Groves PH, Lewis MJ, Cheadle HA, Penny WJ. SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation 1993; 87: 590-597.
33. Schaub RG, Simmons CA, Koets MH, Romano PJ, Steward GJ. Early events in the formation of a venous thrombus following local trauma and stasis. Lab Invent 1984; 51: 218-224.
34. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leucocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655.
35. Provst P, Lam JYT, Lacoste L, Merhi Y, Waters D. Endothelium-derived nitric oxide attenuates neutrophil adhesion to endothelium under arterial flow conditions. Arteriolscler Thromb 1994; 14: 331-335.
36. Nishimura H, Tsuji H, Masuda H et al. Angiotensin II Increases Plasminogen Activator Inhibitor-1 and Tissue Factor mRNA expression without changing that of Tissue Type Plasminogen Activator or Tissue Factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-1195.
37. Korbut R, Lidbury PS, Vane JR. Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet 1990; 335: 669.
38. Seljeflot I, Moan A, Kjeldsen S, Sandvic E, Arnesen H. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299-1304.
39. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G. Role of endothelium - derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990; 86: 1769-1771.
40. Wollny T, Iacoviello L, Buczko W, de Gaetano G, Donati MB. Prolongation of bleeding time by acute hemolysis in rats: a role for nitric oxide. Am J Physiol 1997; 272: H2875-H2884.
41. Chabielska E, Pawlak P, Buczko W. Effects of drugs affecting the renin-angiotensin system on venous thrombosis in normotensive rats. Pol J Pharmacol 1996; 48: 89-91.
42. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.